Melanomas with mutated glucose-6-phosphate dehydrogenase (G6PD), a key enzyme in the pentose phosphate pathway, were found to have higher levels of oxidative stress, highlighting G6PD inhibition as a potential therapeutic target [212]. The gene discussed is G6PD; the disease is melanoma.